AVIDa-hIL6: A Large-Scale VHH Dataset Produced from an Immunized Alpaca for Predicting Antigen-Antibody Interactions

Hirofumi Tsuruta,Hiroyuki Yamazaki,Ryota Maeda,Ryotaro Tamura,Jennifer N. Wei,Zelda Mariet,Poomarin Phloyphisut,Hidetoshi Shimokawa,Joseph R. Ledsam,Lucy Colwell,Akihiro Imura
2023-10-11
Abstract:Antibodies have become an important class of therapeutic agents to treat human diseases. To accelerate therapeutic antibody discovery, computational methods, especially machine learning, have attracted considerable interest for predicting specific interactions between antibody candidates and target antigens such as viruses and bacteria. However, the publicly available datasets in existing works have notable limitations, such as small sizes and the lack of non-binding samples and exact amino acid sequences. To overcome these limitations, we have developed AVIDa-hIL6, a large-scale dataset for predicting antigen-antibody interactions in the variable domain of heavy chain of heavy chain antibodies (VHHs), produced from an alpaca immunized with the human interleukin-6 (IL-6) protein, as antigens. By leveraging the simple structure of VHHs, which facilitates identification of full-length amino acid sequences by DNA sequencing technology, AVIDa-hIL6 contains 573,891 antigen-VHH pairs with amino acid sequences. All the antigen-VHH pairs have reliable labels for binding or non-binding, as generated by a novel labeling method. Furthermore, via introduction of artificial mutations, AVIDa-hIL6 contains 30 different mutants in addition to wild-type IL-6 protein. This characteristic provides opportunities to develop machine learning models for predicting changes in antibody binding by antigen mutations. We report experimental benchmark results on AVIDa-hIL6 by using machine learning models. The results indicate that the existing models have potential, but further research is needed to generalize them to predict effective antibodies against unknown mutants. The dataset is available at <a class="link-external link-https" href="https://avida-hil6.cognanous.com" rel="external noopener nofollow">this https URL</a>.
Machine Learning,Quantitative Methods
What problem does this paper attempt to address?
The main problem this paper attempts to address is the small scale of existing antibody-antigen interaction datasets, the lack of non-binding samples, and the issue of precise amino acid sequences. To accelerate the discovery of therapeutic antibodies, researchers have developed A VIDa-hIL6, a large-scale dataset for predicting interactions between heavy chain antibodies (VHH) and antigens. This dataset is generated by immunizing camels (specifically alpacas) using the human interleukin-6 (IL-6) protein as the antigen. A VIDa-hIL6 contains 573,891 antigen-VHH pairs, each with reliable binding or non-binding labels, and also includes 30 different IL-6 mutants, providing an opportunity to predict the impact of antigen mutations on antibody binding. Specifically, the study aims to: 1. **Construct a large-scale, high-quality dataset**: A VIDa-hIL6 is currently the largest antibody-antigen interaction dataset, 10 times larger than other publicly available datasets, containing amino acid sequences of antigens and antibodies as well as binary labels for binding and non-binding. 2. **Increase the diversity of the dataset**: The dataset includes not only wild-type IL-6 proteins but also 30 different artificial point mutants, which can be used to study how single amino acid changes affect antibody binding. 3. **Develop new data generation methods**: Researchers utilized the immune system of live alpacas to generate data and designed a new data labeling method to ensure the reliability of the labels. 4. **Evaluate the performance of machine learning models**: Through benchmarking, researchers assessed the performance of existing machine learning models in predicting antibody binding to unknown mutants. The results show that existing models have potential but require further research to improve their generalization capabilities. In summary, this paper provides an important resource and tool for accelerating the discovery of therapeutic antibodies by constructing the A VIDa-hIL6 dataset.